The company's latest restructuring announcement isn't sitting well with investors.
News & Analysis: Dynavax Technologies
Heplisav-B's commercial launch is starting to ramp up.
DVAX earnings call for the period ending March 31, 2019.
The biotech's limited cash runway is starting to weigh on its shares.
DVAX earnings call for the period ending December 31, 2018.
Dynavax's stock did a U-turn in January. Here's why.
Dynavax had a terrible 2018. Here's why.
Investors worried disappointing vaccine sales won't improve in 2019 sent the stock tumbling.
Preliminary data that looked good on the surface left investors with more questions than answers.
If you're looking for high-reward stocks, these three could pay off big.